End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) to $95 from $98 while keeping its Buy rating on the stock. The analyst also reduced its risk-adjusted peak sales forecast for Apogee’s ’279 combination therapy from $1.8 billion to $1.6 billion to reflect potential limitations in high-risk patients.

Jefferies’ price target adjustment on Apogee Therapeutics Inc. (NASDAQ:APGE) stock followed a 6% fall in the biotechnology company’s share price after Amgen discontinued its OX40 collaboration with Kyowa Kirin and Sanofi deprioritized amlitelimab in certain non-atopic dermatitis indications. The analyst also noted that it does not anticipate Kaposi’s Sarcoma to significantly impact the commercial potential of OX40 therapies; however, a potential black box warning for high-risk populations is anticipated, despite expectations for a better safety profile compared to JAK inhibitors.

Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that develops treatments for atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications.

While we acknowledge the risk and potential of APGE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than APGE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Best High-Upside Materials Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.